Journals / MN Oftalmoloji / 2015 / Cilt: 22 - Sayı: 3

Intravitreal Bevacizumab Therapy for Choroidal Neovascular Membrane Secondary to Presumed Ocular Histoplasmosis Syndrome

Olası Oküler Histoplazmozis Sendromuna Bağlı Koroidal Neovasküler Membranın İntravitreal Bevacizumab ile Tedavisi

Pages
189–191
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here a treatment of recurrent CNVM secondary to POHS with a single dose of intravitreal bevacizumab is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ocular histoplasmosis is a disease that can lead to severe visual loss in young adults.
📊
Key Findings & Data:Presumed ocular histoplasmosis syndrome (POHS) should be kept in mind in younger patients with multiple chorioretinal lesions, peripapillary atrophy and maculopathy caused by choroidal neovascular membrane (CNVM).
💡
Conclusion & Impact:Here a treatment of recurrent CNVM secondary to POHS with a single dose of intravitreal bevacizumab is presented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ocular histoplasmosis is a disease that can lead to severe visual loss in young adults. Presumed ocular histoplasmosis syndrome (POHS) should be kept in mind in younger patients with multiple chorioretinal lesions, peripapillary atrophy and maculopathy caused by choroidal neovascular membrane (CNVM). Here a treatment of recurrent CNVM secondary to POHS with a single dose of intravitreal bevacizumab is presented.

Özet

Oküler histoplazmozis genç erişkinlerde ağır görme kaybına yol açabilen bir hastalıktır. Çok sayıda koryoretinal lezyonlar, peripapiller atrofi ve koroidal neovasküler membrana (KNVM) bağlı makülopatisi olan genç hastalarda olası oküler histoplazmozis sendromu (OOHS) akılda tutulmalıdır. Bu yazıda OOHS'a bağlı nüks KNVM gelişen bir hastanın tek doz intravitreal bevacizumab ile tedavisi sunulmuştur.

🔖

Cite This Article

PARLAKFİKİRER, N., İLHAN, N., COŞKUN, M., TUZCU, E. A., İLHAN, Ö. (2015). Intravitreal Bevacizumab Therapy for Choroidal Neovascular Membrane Secondary to Presumed Ocular Histoplasmosis Syndrome. MN Oftalmoloji, Cilt: 22 - Sayı: 3, 189–191. https://ajindex.com/articles/295637

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Prasad AG, Van Gelder RN. Presumed ocular histoplasmosis syndrome. Curr Opin Ophthalmol 2005;16(6):364-8
  2. Ciulla TA, Piper HC, Xiao M, Wheat LJ. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. Curr Opin Ophthalmol 2001;12:442-9
  3. Olk RJ, Burgess DB, McCormick PA. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology 1984;91 (12):1592-602
  4. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103(8):1241-4
  5. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol 1987; 105(11):1499-507
  6. Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003; 136(4):739-41
  7. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with vertepor - fin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 2002;109 (8):1499-505
  8. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinico - pathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135(3):343-50
  9. Nielsen JS, Fick TA, Saggau DD, Barnes CH. Intravitreal antivascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina 2012;32(3):468-72
  10. Ehrlich R, Ciulla TA, Maturi R, et al. Intravitreal bevacizumab for coroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. Retina 2009;29(10):1418-23.